27
Participants
Start Date
July 30, 2020
Primary Completion Date
February 17, 2022
Study Completion Date
February 17, 2022
Active Investigational Treatment ENT-01
ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
Icahn School of Medicine at Mount Sinai, New York
Albany Medical College, Albany
Dartmouth Hitchcock Medical Center, Lebanon
Penn State University, Hershey
Georgetown Universtiy, Department of Neurology, Washington D.C.
University Physicians & Surgeons, Inc. dba Marshall Health, Huntington
Premiere Research Institute at Palm Beach Neurology, West Palm Beach
JEM Research Institute, Atlantis
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
USF Health Byrd Parkinson's Disease Movement Disorders Center of Excellence, Tampa
Parkinson's Disease Treatment Center of SWFL, Port Charlotte
Intercoastal Medical Group, Sarasota
University of Toledo Medical Center, Toledo
Cleveland Clinic, Cleveland
Rocky Mountain Movement Disorders Center, Englewood
SC3 Research - Pasadena, Pasadena
The Parkinson's and Movement Disorder Institute, Fountain Valley
Evergreen Health - Booth Gardner Parkinson's Care Center, Kirkland
Lead Sponsor
Enterin Inc.
INDUSTRY